The Conversation (0)
Miraculins Inc. (TSXV:MOM) reported positive results from its first pharmacy pilot for the Scout DS® Diabetes Screening Kiosk. To date, the kiosk has identified elevated risk for pre-diabetes or type 2 diabetes in 41% or 145 individuals in 16 days. The pilot has screened and surveyed over 350 individuals in two locations in Ontario, and will continue until mid-March. Due to the promising pilot results, Miraculins plans to continue to develop a business model for the pharmacy sector where retailers could lease the turn-key and fully-staffed Scout DS® diabetes screening and consumer survey kiosks on a weekly, monthly, or longer-term basis.
As quoted in the press release:
The Company also reports that pilot participants were pleased to complete a touch-screen survey while seated for their complimentary and non-invasive Scout DS® diabetes test, which resulted in the acquisition of valuable and traditionally difficult to procure consumer information. The survey was specifically tailored to help identify opportunities for the provision of enhanced healthcare and customer service, while isolating pathways for the pharmacy to potentially increase its revenues related to diabetes care and corresponding lifestyle change management. Both the screening and survey were preceded by participating individuals signing a consent form.
“Based upon the willingness of pharmacy pilot customers to complete a survey while being tested, we believe that our diabetes screening and consumer survey kiosk may also have the potential to be integrated into retail store operations with large customer bases in other major sectors, as well as into shopping malls, airports and a variety of public settings,” said Paul Moreau, Vice President Sales and Marketing for Miraculins. “Retailers, organizations and marquee brands in North America and abroad highly value actionable consumer information, which in practice is very hard to get. We believe they could use our kiosk to procure that data and deliver a brand message, while providing an important, complimentary healthcare screen to their customers for what is now being described as the fastest growing disease in history.”
As a result of these promising pilot results, the Company plans to continue to develop a business model for the pharmacy sector (adaptable for non-pharmacy applications as well) where retailers could lease the turn-key and fully-staffed Scout DS® diabetes screening and consumer survey kiosks on a weekly, monthly, or longer-term basis. As individuals with normal Scout DS® results are recommended to be re-tested annually, the kiosk has a recurring customer contact and outreach feature built-in. Additional pilots for the pharmacy sector are being planned.
Click here to read the Miraculins Inc. (TSXV:MOM) press release
Click here to see the Miraculins Inc. (TSXV:MOM) profile.